

For Immediate Release
For Further Information Contact:
Andrew Fisher at (202) 483-7000
Email: Afisher@unither.com

**REMODULIN ADDED TO FEDERAL SUPPLY SCHEDULE AS
FINAL UNITED STATES REIMBURSEMENT APPROVAL**

Silver Spring, MD, January 10, 2003: United Therapeutics Corporation (NASDAQ: UTHR) announced today that Remodulin® has been approved for inclusion in the Federal Supply Schedule of the General Services Administration. The Federal Supply Schedule is a listing of all products and services that federal departments and agencies in the United States may purchase in an expedited fashion. The Department of Veteran Affairs, the Department of Defense, the Public Health Service and the Indian Health Service, among other agencies, may now purchase Remodulin.

“With this final reimbursement approval now in place, we have obtained all necessary federal and state approvals for the purchase and reimbursement of Remodulin in the United States,” said Fred Hadeed, United Therapeutics’ Chief Financial Officer.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.

* * *